Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Sky One Medical has announced that its subsidiary, Heilongjiang Tianlong Pharmaceuticals, has obtained approvals for two new drugs - Oxymetazoline Hydrochloride nasal drops and Taurine eye drops, from the SFDA.
Subscribe to our email newsletter
Oxymetazoline Hydrochloride nasal drops is approved for the treatment of acute and chronic rhinitis, sinusitis and allergic rhinitis. Taurine eye drops is approved for the treatment of acute and chronic conjunctivitis.
The company is still aggressively seeking approval for other drugs with large market potential. By the end of 2008, the company will have a total 38 new drugs submitted to the SFDA approval.
Yan-qing Liu, chairman, CEO and director of China Sky One Medical, said: “We believe that the commercialization of these two products will provide a steady revenue for China Sky One and further improve our profitability in the years ahead.”